A Randomized, Placebo-controlled, Parallel Panel Study to Assess the Effects of REGN3500, Dupilumab, and Combination of REGN3500 Plus Dupilumab on Markers of Inflammation After Bronchial Allergen Challenge in Patients With Allergic Asthma
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Dupilumab (Primary) ; Itepekimab (Primary) ; Fluticasone propionate
- Indications Allergic asthma
- Focus Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 16 Jan 2020 Status changed from active, no longer recruiting to completed.
- 17 Jul 2019 Planned End Date changed from 29 Jan 2020 to 9 Dec 2019.
- 17 Jul 2019 Status changed from recruiting to active, no longer recruiting.